J Pathol Transl Med.  2021 May;55(3):171-180. 10.4132/jptm.2021.02.27.

Hepatocellular adenomas: recent updates

• Kim H
• Park YN

• KMID: 2515922
• DOI: http://doi.org/10.4132/jptm.2021.02.27

Abstract

Hepatocellular adenoma (HCA) is a heterogeneous entity, from both the histomorphological and molecular aspects, and the resultant subclassification has brought a strong translational impact for both pathologists and clinicians. In this review, we provide an overview of the recent updates on HCA from the pathologists’ perspective and discuss several practical issues and pitfalls that may be useful for diagnostic practice.

Keyword

Hepatocellular adenoma; Classification; Pathology

Figure

• 

  Fig. 1 Inflammatory hepatocellular adenoma. Sinusoidal dilatation, congestion and peliosis is seen in the tumor (A–C). Inflammatory cell infiltration (C), thick arteriolar structures with ductular reaction, resembling portal tracts (“pseudo-portal tracts”) and steatosis (D) may be seen in these tumors. Diffuse steatosis may be seen in the background liver (A). The tumor cells express serum amyloid A (E; inset: granular cytoplasmic staining in tumor cells) and C-reactive peptide (F).

• 

  Fig. 2 β-catenin–activated hepatocellular adenoma (B-HCA). There is mild trabecular thickening (A) and pseudoglandular structures (B, C). Mild cytological atypia is present (A–C). Cholestasis may be seen (C). On immunohistochemistry, B-HCA with strong β-catenin activation (Bex3-HCA) demonstrates nuclear β-catenin expression (D), instead of the normal membranous pattern (inset), and diffuse homogeneous glutamine synthetase expression is seen in such tumors (E, inset: higher-power view).

• 

  Fig. 3 Immunohistochemical correlates of CTNNB1 alteration status in β-catenin-activated HCA, FNH and normal liver. FNH, focal nodular hyperplasia; HCA, hepatocellular adenoma. aSerum amyloid A and/or reactive peptide is additionally expressed in β-catenin-activated inflammatory HCA.

• 

  Fig. 4 HNF1A-inactivated hepatocellular adenoma. Diffuse steatosis is seen in the tumor, compared to the surrounding hepatic parenchyme (A–C). There is no significant cytological or architectural atypia on higher-power magnification (B). Immunohistochemically, the tumor displays loss of liver fatty acid-binding protein expression (C) (dotted line: tumor).

• 

  Fig. 5 Atypia in hepatocellular neoplasms. When features atypical for hepatocellular adenomas, such as frequent pseudoglandular structures (A, C–E), nuclear atypia (B, C) and focal reticulin loss (D; inset: preserved reticulin framework for comparison), are identified, the differential diagnosis should be between atypical hepatocellular neoplasm and well-differentiated hepatocellular carcinoma. When these features are only focally present (< 5%), the terminology of atypical hepatocellular neoplasm may be used. Nuclear β-catenin expression is often identified in such cases (E).

• 

  Fig. 6 Focal nodular hyperplasia. A typical low power view of a resected case (A). A central stellate scar with radiating fibrous septa is seen, containing multiple irregular-shaped vascular structures. When needle biopsy specimens are obtained from the central scar or fibrous septa (B, C), it is easy to identify the abnormal vascular channels with varying calibers, shape and irregular walk thickness. Sometimes biopsies include the peripheral portions without the obvious vascular anomalies; instead there is at least mild hepatocellular nodularity with ductular reaction (D). Glutamine synthetase immunohistochemistry demonstrates broad bands of GS-expressing hepatocytes (E), which corresponds to the map-like pattern in Fig. 3, in contrast to the normal perivenular pattern (arrows).

Reference

References

1. Bioulac-Sage P, Kakar S, Nault JC. Hepatocellular adenoma. WHO classification of tumours: digestive system tumours. 5th ed. Lyon: International Agency for Research on Cancer;2019. p. 224–8.

2. Lin H, van den Esschert J, Liu C, van Gulik TM. Systematic review of hepatocellular adenoma in China and other regions. J Gastroenterol Hepatol. 2011; 26:28–35.

3. Sasaki M, Yoneda N, Kitamura S, Sato Y, Nakanuma Y. Characterization of hepatocellular adenoma based on the phenotypic classification: the Kanazawa experience. Hepatol Res. 2011; 41:982–8.

4. Sasaki M, Nakanuma Y. Overview of hepatocellular adenoma in Japan. Int J Hepatol. 2012; 2012:648131.

5. Liu HP, Zhao Q, Jin GZ, et al. Unique genetic alterations and clinicopathological features of hepatocellular adenoma in Chinese population. Pathol Res Pract. 2015; 211:918–24.

6. Huang WC, Liau JY, Jeng YM, et al. Hepatocellular adenoma in Taiwan: distinct ensemble of male predominance, overweight/obesity, and inflammatory subtype. J Gastroenterol Hepatol. 2020; 35:680–8.

7. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology. 2006; 43:515–24.

8. Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology. 2013; 144:888–902.

9. Scoazec JY. Hepatocellular adenomas: one step beyond. Gut. 2019; 68:1140–2.

10. Nault JC, Couchy G, Balabaud C, et al. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017; 152:880–94.

11. Nault JC, Zucman Rossi J. Molecular classification of hepatocellular adenomas. Int J Hepatol. 2013; 2013:315947.

12. Shin JH, Yu E, Kim EN, Kim CJ. C-reactive protein overexpression in the background liver of hepatitis B virus-associated hepatocellular carcinoma is a prognostic biomarker. J Pathol Transl Med. 2018; 52:267–74.

13. Rebouissou S, Franconi A, Calderaro J, et al. Genotype-phenotype correlation of CTNNB1 mutations reveals different β-catenin activity associated with liver tumor progression. Hepatology. 2016; 64:2047–61.

14. Pilati C, Letouze E, Nault JC, et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell. 2014; 25:428–41.

15. Mounajjed T, Yasir S, Aleff PA, Torbenson MS. Pigmented hepatocellular adenomas have a high risk of atypia and malignancy. Mod Pathol. 2015; 28:1265–74.

16. Bioulac-Sage P, Sempoux C, Balabaud C. Hepatocellular adenoma: classification, variants and clinical relevance. Semin Diagn Pathol. 2017; 34:112–25.

17. Cappellen D, Balabaud C, Bioulac-Sage P. A difficult case of betacatenin-mutated hepatocellular adenoma: a lesson for diagnosis. Histopathology. 2019; 74:355–7.

18. Ibarrola C, Castellano VM, Colina F. Focal hyperplastic hepatocellular nodules in hepatic venous outflow obstruction: a clinicopathological study of four patients and 24 nodules. Histopathology. 2004; 44:172–9.

19. Paradis V, Bioulac-Sage P, Balabaud C. Congenital hepatic fibrosis with multiple HNF1alpha hepatocellular adenomas. Clin Res Hepatol Gastroenterol. 2014; 38:e115–6.

20. Lee Y, Park H, Lee K, Lee Y, Lee K, Kim H. Multiple hepatocyte nuclear factor 1A (HNF1A)-inactivated hepatocellular adenomas arising in a background of congenital hepatic fibrosis. J Pathol Transl Med. 2021; 55:154–8.

21. Sempoux C, Balabaud C, Paradis V, Bioulac-Sage P. Hepatocellular nodules in vascular liver diseases. Virchows Arch. 2018; 473:33–44.

22. Frulio N, Balabaud C, Laurent C, Trillaud H, Bioulac-Sage P. Unclassified hepatocellular adenoma expressing ASS1 associated with inflammatory hepatocellular adenomas. Clin Res Hepatol Gastroenterol. 2019; 43:e63–7.

23. Henriet E, Abou Hammoud A, Dupuy JW, et al. Argininosuccinate synthase 1 (ASS1): a marker of unclassified hepatocellular adenoma and high bleeding risk. Hepatology. 2017; 66:2016–28.

24. Nault JC, Couchy G, Caruso S, et al. Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology. 2018; 68:964–76.

25. Sala M, Gonzales D, Leste-Lasserre T, et al. ASS1 overexpression: a hallmark of sonic Hedgehog hepatocellular adenomas: recommendations for clinical practice. Hepatol Commun. 2020; 4:809–24.

26. Singhi AD, Jain D, Kakar S, Wu TT, Yeh MM, Torbenson M. Reticulin loss in benign fatty liver: an important diagnostic pitfall when considering a diagnosis of hepatocellular carcinoma. Am J Surg Pathol. 2012; 36:710–5.

27. Kim H, Park YN. Role of biopsy sampling for diagnosis of early and progressed hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2014; 28:813–29.

28. Di Tommaso L, Destro A, Seok JY, et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol. 2009; 50:746–54.

29. Lagana SM, Salomao M, Bao F, Moreira RK, Lefkowitch JH, Remotti HE. Utility of an immunohistochemical panel consisting of glypican-3, heat-shock protein-70, and glutamine synthetase in the distinction of low-grade hepatocellular carcinoma from hepatocellular adenoma. Appl Immunohistochem Mol Morphol. 2013; 21:170–6.

30. Choi WT, Kakar S. Atypical hepatocellular neoplasms: review of clinical, morphologic, immunohistochemical, molecular, and cytogenetic features. Adv Anat Pathol. 2018; 25:254–62.

31. Evason KJ, Grenert JP, Ferrell LD, Kakar S. Atypical hepatocellular adenoma-like neoplasms with beta-catenin activation show cytogenetic alterations similar to well-differentiated hepatocellular carcinomas. Hum Pathol. 2013; 44:750–8.

32. Kakar S, Evason KJ, Ferrell LD. Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category: reply. Hum Pathol. 2014; 45:660–1.

33. Roncalli M, Sciarra A, Tommaso LD. Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol. 2016; 22:199–211.

34. Laumonier H, Frulio N, Laurent C, Balabaud C, Zucman-Rossi J, Bioulac-Sage P. Focal nodular hyperplasia with major sinusoidal dilatation: a misleading entity. BMJ Case Rep. 2010; 2010:bcr0920103311.

35. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology. 2004; 126:1323–9.

36. Bioulac-Sage P, Rebouissou S, Sa Cunha A, et al. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver. Gastroenterology. 2005; 128:1211–8.

37. Bioulac-Sage P, Cubel G, Taouji S, et al. Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes. Am J Surg Pathol. 2012; 36:1691–9.

38. Joseph NM, Ferrell LD, Jain D, et al. Diagnostic utility and limitations of glutamine synthetase and serum amyloid-associated protein immunohistochemistry in the distinction of focal nodular hyperplasia and inflammatory hepatocellular adenoma. Mod Pathol. 2014; 27:62–72.

39. Agostini-Vulaj D, Sharma AK, Findeis-Hosey JJ, McMahon LA, Gonzalez RS. Distinction between inflammatory hepatocellular adenoma and mass effect on liver sampling. Hum Pathol. 2017; 61:105–10.

40. Kim H, Lee H, Park YN. Loss of liver fatty acid binding protein expression in hepatocellular carcinomas is associated with a decreased recurrence-free survival. J Liver Cancer. 2015; 15:30–5.

41. Liu L, Shah SS, Naini BV, et al. Immunostains used to subtype hepatic adenomas do not distinguish hepatic adenomas from hepatocellular carcinomas. Am J Surg Pathol. 2016; 40:1062–9.

42. Torbenson M. Hepatic adenomas: classification, controversies, and consensus. Surg Pathol Clin. 2018; 11:351–66.

43. Sasaki M, Yoneda N, Kitamura S, Sato Y, Nakanuma Y. A serum amyloid A-positive hepatocellular neoplasm arising in alcoholic cirrhosis: a previously unrecognized type of inflammatory hepatocellular tumor. Mod Pathol. 2012; 25:1584–93.

44. Di Tommaso L, Franchi G, Park YN, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007; 45:725–34.